Results 51 to 60 of about 6,667,826 (304)

Patient-tailored analysis of minimal residual disease in acute myeloid leukemia using next generation sequencing. [PDF]

, 2016
Next generation sequencing techniques have revealed that leukemic cells in acute myeloid leukemia often are characterized by a limited number of somatic mutations. These mutations can be the basis for detection of leukemic cells in follow-up samples. The
Fogelstrand, Linda, Abrahamsson, Jonas, Samuelsson, Tore,, Pettersson, Louise,, Ståhlman, Sara, Malmberg, Erik B R, Rehammar, Anna, Palmqvist, Lars,, Rehammar, Anna,, Alm, Sofie J, Malmberg, Erik Br,, Abrahamsson, Jonas,, Kristiansson, Erik,, Samuelsson, Tore, Palmqvist, Lars, Kristiansson, Erik, Ehinger, Mats, Alm, Sofie J., Garelius, Hege, Alm, Sofie J,, Ståhlman, Sara,, Malmberg, Erik Br, Ehinger, Mats,, Garelius, Hege,, Fogelstrand, Linda,, Pettersson, Louise, St\ue5hlman, Sara, Malmberg, Erik,, Alm, Sofie J.,, Delsing Malmberg, Erik, Lund University., Malmberg, Erik B R,   +31 more
core   +1 more source

Retrospective Analysis of Donor Lymphocyte Infusions in Pediatric Patients With Mixed Chimerism After Hematopoietic Stem Cell Transplantation

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Allogeneic hematopoietic stem cell transplantation (alloHSCT) is an essential therapy for several malignant and nonmalignant diseases, but relapse and graft loss remain the principal threats to its success. Routine monitoring of chimerism and minimal residual disease (MRD) enables early detection of imminent recurrence and guides ...
Carmen Junk, Sebastian Michaelis, Michaela Döring, Thomas Eichholz, Ursula Holzer, Martin Ebinger, Tim Flaadt, Rupert Handgretinger, Peter Lang, Jan Frederic Weller, Markus Mezger   +10 more
wiley   +1 more source

Evaluation of models to predict residual disease.

, 2018
Evaluation of models to predict residual disease.
Young Tae Kim (244433), Yun-Ji Kim (591566), Jung-Yun Lee (612097), Eun Ji Nam (1447849), Sunghoon Kim (138767), In Ha Lee (5724995), Sang Wun Kim (4413214), Young Shin Chung (4413211), Yong Jae Lee (213134)   +8 more
core   +1 more source

Pediatric Idiopathic Multicentric Castleman Disease Is Often Severe But Responsive to Siltuximab

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Idiopathic multicentric Castleman disease (iMCD) is a potentially fatal immunologic disorder marked by widespread lymphadenopathy and inflammation. Siltuximab, an interleukin‐6 (IL‐6) inhibitor, is the only FDA‐approved treatment for adult patients with iMCD.
Bridget Austin, Sheila K. Pierson, Kelley C. Dacus, Mateo Sarmiento Bustamante, Saishravan Shyamsundar, Larissa Borys, Kayla McHugh, Abiola Irvine, Yoojin Jo, Adam Bagg, Mary Jo Lechowicz, Daisy Alapat, Amy Chadburn, Megan S. Lim, Gordan Srkalovic, Frits van Rhee, David C. Fajgenbaum, Joshua D. Brandstadter   +17 more
wiley   +1 more source

Supplementary Table 3 from A Prognostic Model Based on Residual Cancer Burden and Tumor-Infiltrating Lymphocytes on Residual Disease after Neoadjuvant Therapy in HER2+ Breast Cancer

, 2023
Supplementary Table 3 – Multivariate Cox analysis for disease-free survival (DFS) in patients with residual disease (RD) after ...
Moira Ragazzi (16677432), Gaia Griguolo (15026043), Giancarlo Bisagni (16677477), Bethania Fernandes (16677435), Leocadia Dore (16677459), Marcello Lo Mele (16677468), Alberto Zambelli (16677474), Giacomo Santandrea (16677465), Davide Massa (16677438), Mariangela Gaudio (16677462), Michele Bottosso (16677444), Daniela Iannaccone (16677456), Alessandra Bisagni (16677447), Fabio Girardi (16677441), Giovanni Zarrilli (16677450), Rita De Sanctis (16677471), Valentina Guarneri (16677480), Maria Vittoria Dieci (15026025), Federica Miglietta (16677429), Matteo Fassan (8808827), Francesca Porra (16677453)   +20 more
core   +1 more source

The Impact of the COVID‐19 Pandemic on Childhood Cancer Survival: A Population‐Based Assessment of Survival Patterns Between 2015 and 2023 in Germany

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Numerous international studies have reported declines in new cancer diagnoses, delayed diagnoses and disruptions in cancer treatment following the implementation of COVID‐19 pandemic public health measures, raising concerns that these effects may ultimately contribute to increased cancer mortality.
Friederike Erdmann, Maike Wellbrock, Javier Louro, Arndt Borkhardt, Martin Schrappe, Claudia Trübenbach, Desiree Grabow, Cécile M. Ronckers, Joachim Schüz   +8 more
wiley   +1 more source

Referral Patterns and Diagnostic Timeliness in Pediatric Cancer: A Hospital‐Based Study in Indonesia

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Timely diagnosis and treatment are critical for improving survival among children with cancer. In low‐ and middle‐income countries (LMICs), delays are common and may be influenced by fragmented referral pathways and diagnostic limitations.
Nur Melani Sari, Regina Hadi Putri, Fatimah Assyifa, Judith Spijkerman, Gertjan Johannes Kaspers, Susi Susanah   +5 more
wiley   +1 more source

Plasticity of Non-Apoptotic Residual Tumor Cells After Neoadjuvant Immunochemotherapy: Epigenetic and Microenvironmental Determinants

Biomolecules
Neoadjuvant immunochemotherapy (NICT), mainly anti-PD-1/PD-L1 therapy combined with cytotoxic chemotherapy, significantly improved perioperative outcomes for resectable solid tumors such as lung cancer and breast cancer.
Wenjun Meng, Ruiyue Li, Peiliang Xie, Bangyi Xiang, Qing Li   +4 more
doaj   +1 more source

Does Unplanned Soft Tissue Sarcoma Surgery Have a Negative Effect on Prognosis?

Journal of Investigative Surgery, 2022
Background We aimed to compare the oncological outcomes of patients who underwent re-excision following unplanned surgery and those who underwent planned surgery.
Bülent Erol, Özgür Baysal
doaj   +1 more source

Venetoclax‐Based Therapy as a Bridge to Hematopoietic Stem Cell Transplantation in Relapsed or Refractory Pediatric Acute Leukemia

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Relapsed and/or refractory (R/R) pediatric acute leukemia carries a dismal prognosis, largely driven by chemoresistance to conventional salvage therapy. The BH3‐mimetic venetoclax, combined with chemotherapy or hypomethylating agents, has demonstrated efficacy in small clinical trials.
Katherine S. Colman, Deborah Meyran, Vajiranee Malalasekera, Heather Weerdenburg, Janine Campbell, Rachel Conyers, Stacie Wang, Hannah Walker, Seong Lin Khaw, Diane Hanna   +9 more
wiley   +1 more source